Patent intelligence · EP
EP 2511275
Neuartige Piperidinyl-monocarboxylsäuren als S1P1 Rezeptoragonisten
Neuartige Piperidinyl-monocarboxylsäuren als S1P1 Rezeptoragonisten
Patent details — EP 2511275
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Oct 17, 2012
- Expiration
- Oct 12, 2032
- Applicant
- BIOPROJET SOC CIV [FR]
- CPC classes
- A61K 31/ 454 A I, A61K/31454, A61K/4506, A61P 9/ 10 A I
Quick answer
EP 2511275 (Neuartige Piperidinyl-monocarboxylsäuren als S1P1 Rezeptoragonisten) is held by BIOPROJET SOC CIV [FR]. Status: granted. Granted Oct 17, 2012. Expires Oct 12, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOPROJET SOC CIV [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 454 A I, A61K/31454, A61K/4506, A61P 9/ 10 A I, A61P 29/ 00 A I, A61P 35/ 00 A I
More from BIOPROJET SOC CIV [FR]
Related pharmaceutical patents in our USPTO index.
-
EP 4732903
COKRISTALLE VON PITOLISTANTHYDROCHLORID
granted -
EP 4681704
NEUE FORMULIERUNGEN VON PITOLISANT
granted -
US 2025120959
NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE
granted -
US 2024327366
POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE
granted -
EP 3906927
VERWENDUNG VON DOPAMIN-D3-TEILAGONISTEN ZUR BEHANDLUNG VON STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS
granted -
US 2020024256
TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
granted -
EP 3378477
NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN
granted
Frequently asked questions
What is US patent 2511275?
EP 2511275 (Neuartige Piperidinyl-monocarboxylsäuren als S1P1 Rezeptoragonisten) is held by BIOPROJET SOC CIV [FR]. Status: granted. Granted Oct 17, 2012. Expires Oct 12, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2511275?
BIOPROJET SOC CIV [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does EP 2511275 expire?
Our index shows an expiration date of Oct 12, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.